We are experts in RNA biology, design and implementation of bioproduction platforms for therapeutic products.
Our disruptive technology uses eucaryotic cell biofactories to make high-quality messenger RNA (mRNAs).
Our bioproduction technology will help mass produce mRNA and enhance productivity at a fraction of the current cost.
By perfecting an overlooked mRNA production method, we are helping build a more sustainable planet, save cancer patients and give their grand-children a future.
We isolate the therapeutic mRNA in a subcompartment within the cell. The capsule containing the desired mRNA can then be extracted.
Master Cell Bank
Using our proprietary recombinant cell platform we optimize the expression of the mRNA of interest.
Leveraving industrial extraction and purification processes we achieve high levels of purity.
Our patented technology allows us to accumulate mRNA inside cell subparts, avoiding degradation by RNAses.
Each step is precisely analyzed and controlled to allow for GMP-grade production.
Messenger RNAs are highly valuable for human health. They helped to quickly develop effective Covid-19 vaccines critical for pandemic response. But their therapeutic applications extend far beyond infectious diseases.
After Covid, mRNA vaccines will tackle diseases as fearsome as HIV and as common as influenza.
mRNAs encoding cancer antigens help immune cells destroy tumors and substantially extend survival.
RNA-based gene therapy is capable of delivering a healthy copy of the faulty gene to the cells.